{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '8.2.4.', 'Baseline Evaluations', 'Demographics and other disease-specific baseline characteristics will be summarized for the ITT', 'Analysis Set and Safety Analysis Set.', '8.2.5.', 'Efficacy Analyses', 'Primary analyses of the primary and secondary endpoints will be based on the ITT Analysis Set.', 'To control for the familywise error rate in the testing of primary and secondary endpoints, a', 'hierarchical testing approach will be used in the following order:', '1. ABR in efficacy period (2-sided alpha = 0.05)', '2. ABR in treatment period (2-sided alpha = 0.05)', '3. Annualized spontaneous bleeding rate in efficacy period (2-sided alpha = 0.05)', '4. Annualized joint bleeding rate in efficacy period (2-sided alpha = 0.05)', '5. Change in physical health score and total score of Haem-A-QOL in treatment period', '(2-sided alpha = 0.05)', 'If testing of any of the endpoints is not statistically significant, testing of subsequent endpoints', 'will stop and the null hypotheses for the subsequent tests will not be rejected. The testing of', 'secondary endpoint ABR in the onset period will not be included in this hierarchical testing', 'procedure.', '8.2.5.1.', 'Primary Endpoint', 'The primary analysis will be performed on the ITT Analysis Set and will include all bleeding', 'episodes occurring in the efficacy period (Day 29 to Day 246) including bleeding episode data', 'collected after discontinuation of IMP. If a patient does not have bleeding episode data collected', 'after Day 28 (eg, due to early study discontinuation), the available bleeding episode data starting', 'from Day 1 will be used as bleeding episode data of the fitusiran period in the primary analysis.', 'To avoid confounding the treatment effect, bleeding episode data during and after major surgery,', 'AT administration, major trauma, or initiation of prophylaxis treatment with factor concentrates', 'will be excluded from the primary analysis.', 'The number of bleeding episodes will be analyzed using a negative binomial model with fixed', 'effects of treatment arm and the number of bleeding episodes in the 6 months prior to study entry', '(10 vs >10) and hemophilia type (hemophilia A or B). The logarithm number of days that each', 'patient spends in the efficacy period matching the bleeding episode data being analyzed will be', 'included as an offset variable to account for unequal follow-up time due to early withdrawal or', 'surgery. The p-value comparing bleeding rates in the 2 treatment arms and the ratio of bleeding', 'rates in the fitusiran treatment arm to the on-demand arm along with its 95% CI will be', 'presented. The estimated mean ABRs in each of the 2 treatment arms along with their 95% Cis', 'will be presented from this model. In addition, summary statistics for ABR, including median', 'and interquartile range, will be presented for each treatment arm, where ABR is defined as:', 'total number of qualifying bleeding episodes', 'X 365.25', 'total number of days in the respective period', 'Property of the Sanofi Group - strictly confidential', '68', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Patients who discontinue treatment during the study will be encouraged to continue recording', 'bleeding episode data.', 'Sensitivity analyses will be performed to evaluate the impact of missing data under different', 'missing data mechanisms and details will be specified in the statistical analysis plan.', '8.2.5.2.', 'Secondary Enppoints', 'The bleeding episodes in the treatment period (Day 1 to Day 246), spontaneous bleeding', 'episodes in the efficacy period, joint bleeding episodes in the efficacy period, and bleeding', 'episodes in the onset period will be analyzed using the same method as primary analysis of ABR.', 'Summary statistics, including median and interquartile range, for annualized rates of these', 'endpoints will be reported.', 'The change from baseline in physical health score and total score of Haem-A-QOL will be', 'analyzed using an analysis of covariance (ANCOVA) model with fixed effects of treatment arm,', 'baseline Haem-A-QOL physical health score and total score, the number of bleeding episodes in', 'the 6 months prior to study entry (10 VS >10), and hemophilia type (hemophilia A or B) as', 'covariates. Domain scores for Haem-A-QOL and their changes from baseline will be', 'summarized descriptively by scheduled visit.', '8.2.5.3.', 'Exploratory Enppoints', 'Details of the analyses for the exploratory endpoints will be described in the SAP.', '8.2.6.', 'Pharmacodynamic Analysis', 'AT and thrombin levels will be summarized descriptively by scheduled visit. Mixed models', 'repeated measures analyses may be performed as deemed appropriate. Correlation between AT', 'and thrombin levels may be explored.', '8.2.7.', 'Pharmacokinetic Analysis', 'Pharmacokinetic analyses will be conducted using a population PK approach on patients in the', 'fitusiran arm. The details of the analysis will be presented in a separated population PK analysis', 'plan.', 'In addition to performing population PK analyses, the following PK parameters will be included', 'in an analysis of East Asian patients in the fitusiran arm at East Asian sites: maximum plasma', 'concentration (Cmax), time to maximum plasma concentration (tmax), elimination half-life', 'area under the concentration-time curve (AUC), apparent clearance (CL/F), and apparent volume', 'of distribution (V/F); these parameters will be estimated during the fitusiran treatment period', 'using non-compartmental analysis. Other parameters may be calculated, if deemed necessary.', '8.2.8.', 'Safety Analyses', 'Extent of exposure will be summarized. Safety will be based on all AEs having onset (start or', 'worsening in severity) within the study and on the Safety Analysis Set. Incidence of AEs, AEs', 'by maximum severity, AEs by relationship to study medication, SAEs and AEs leading to', 'discontinuation of treatment will be presented.', 'Property of the Sanofi Group - strictly confidential', '69', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}